Homepage – English 2 - QuickVue At-Home
Introducing the
QuickVue® At‑Home OTC COVID-19 Test
Take 10 Minutes. Take Charge.
Effectively Detects
Omicron & Other Variants
The Quickvue At-Home OTC COVID-19 test can accurately detect the Omicron variant (among others) of the Sars-CoV-2, the potentially deadly virus that can lead to COVID-19.
Introducing the QuickVue®
At‑Home OTC COVID-19 Test
Take 10 Minutes. Take Charge.
Effectively Detects
Omicron & Other Variants
The Quickvue At-Home OTC COVID-19 test can accurately detect the Omicron variant (among others) of the Sars-CoV-2, the potentially deadly virus that can lead to COVID-19.
Fast. Easy. Ready When You Are.

QuickVue At-Home OTC COVID-19 Test lets you get rapid results, in the privacy of your own home. Available over-the-counter, everything you need is in the package and taking the test is simple.

This home test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older. The test to be used in individuals within 6-days of symptom onset or individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

Effectively Detects Omicron & Other Variants
The Quickvue At-Home OTC COVID-19 test can accurately detect the Omicron variant (among others) of the Sars-CoV-2, the potentially deadly virus that can lead to COVID-19.

For more information about the Say Yes! COVID Test program in Pitt County, NC and Chattanooga, TN, or to order your test kit, please visit: sayyescovidtest.org. For the program in Ann Arbor, MI please click here.

To be guided through the testing process, please visit: safercovid.org/mytest

Available in the U.S.
For In Vitro Diagnostic (IVD) Use.

Available in the U.S.
For In Vitro Diagnostic (IVD) Use.

How Does the QuickVue At-Home OTC COVID-19 Test Work?

The test uses a gentle self-collected anterior nasal (nares) swab sample to determine a positive or negative COVID-19 result. The swab is swirled in a tube of reagent solution, then removed, before a test strip is inserted. After ten minutes, you can take the strip out of the tube and see your results.

Here’s a quick overview of how it works:

Before you begin the test, it’s important to first read and closely follow the detailed instructions, included in the package.
For more detailed instructions, watch the video below

Para Español, haga clic aquí »
Before you begin the test, it’s important to first read and closely follow the detailed instructions, included in the package.

The test uses a gentle self-collected anterior nasal (nares) swab sample to determine a positive or negative COVID-19 result. The swab is swirled in a tube of reagent solution, then removed, before a test strip is inserted. After ten minutes, you can take the strip out of the tube and see your results.

Here’s a quick overview of how it works:

For more detailed instructions, watch the video below

Para Español, haga clic aquí »
Before you begin the test, it’s important to first read and closely follow the detailed instructions, included in the package.
Have Additional Questions?
About Quidel® and its QuickVue®
At-Home OTC COVID-19 Test

Quidel is a California-based leading diagnostic manufacturer focused on improving the quality of healthcare throughout the globe. As a trusted innovator in the medical device industry for over 40 years, Quidel launched the QuickVue brand in 1986 with visually read rapid diagnostics focusing on women’s health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test cleared by the FDA for professional use.

Now, the QuickVue At-Home OTC COVID-19 Test utilizes trusted technology used for decades by healthcare professionals and makes simple, easy-to-use COVID-19 tests accessible for the good of our families, our communities and the world.

Meet Douglas Bryant

Quidel President and CEO discusses the company’s ongoing commitment to enhancing the well-being of people worldwide.

About Quidel® and its QuickVue®
At-Home OTC COVID-19 Test

Quidel is a California-based leading diagnostic manufacturer focused on improving the quality of healthcare throughout the globe. As a trusted innovator in the medical device industry for over 40 years, Quidel launched the QuickVue brand in 1986 with visually read rapid diagnostics focusing on women’s health and respiratory diseases. In 1999, QuickVue Influenza A+B was the first visually read rapid test cleared by the FDA for professional use.

Now, the QuickVue At-Home OTC COVID-19 Test utilizes trusted technology used for decades by healthcare professionals and makes simple, easy-to-use COVID-19 tests accessible for the good of our families, our communities and the world.

Meet Douglas Bryant

Quidel President and CEO discusses the company’s ongoing commitment to enhancing the well-being of people worldwide.

Sign Up for E-mail Updates
Be among the first to know about this test’s release date, where to buy it, and more.
By providing your e-mail address you are subscribing to receive marketing messages from Quidel.

    FOR FDA EMERGENCY USE AUTHORIZATION (EUA) ONLY. FOR MORE INFORMATION, CLICK HERE.

    The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals within 6-days of symptom onset or individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

    This test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first six days of symptom onset. This test is also authorized for non-prescription home use with adult collected anterior nasal swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first six days of symptom onset.

    This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

    This product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization (EUA) This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

    Partners of:

    San Diego Padres

    San Diego Loyal

    Chicago Blackhawks

    New York Jets